石四藥集團(02005.HK):頭孢克洛幹混懸劑及甲硝唑片通過一致性評價 司替戊醇幹混懸劑被納入優先審評品種名單
格隆匯4月6日丨石四藥集團(02005.HK)宣佈,公司全資附屬公司石家莊四藥有限公司的頭孢克洛幹混懸劑及甲硝唑片已獲得國家藥品監督管理局批准通過仿製藥質量和療效一致性評價。頭孢克洛幹混懸劑主要用於治療敏感菌株引起的感染,而甲硝唑片主要用於治療和預防由厭氧菌導致的感染。
此外,董事局亦公吿,石家莊四藥有限公司的司替戊醇幹混懸劑已納入國家藥品監督管理局的優先審評品種名單,是集團申報產品首次納入此類名單,也是國內獨家申報。司替戊醇幹混懸劑是符合兒童生理特徵的罕見病藥物,主要用於治療嚴重肌肉震顫性小兒癲癇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.